How Ohio State experts brought us closer to a cancer-free world in 2024
2024 was a year of breakthroughs in cancer care, research and knowledge at Ohio State, where oncology experts look ahead to opportunities to innovate in the years to come.
Related Articles
Pirtobrutinib Improves PFS in Previously Treated CLL/SLL
Pirtobrutinib improved progression-free survival in previously treated chronic lymphocytic leukemia and small lymphocytic lymphoma.
Lancet Breast Cancer Commission Report Addresses Challenges to Reduce Disease Burden
Reshma Jagsi, MD, DPhil, highlights key takeaways from the Lancet Breast Cancer Commission Report and the necessary steps forward emphasized in the report.
NFKB1 Haplotype Decreases Inflammation, Increases Response to Ropeginterferon Alfa-2b in PV and ET
NFKB1 rs230511 reduces inflammation and amplifies responses to ropeginterferon alfa-2b in polycythemia vera and essential thrombocythemia.
Tafasitamab Plus Lenalidomide/Rituximab Improves PFS in Relapsed/Refractory Follicular Lymphoma
Tafasitamab plus lenalidomide and rituximab improved median PFS vs lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.
Designing Trials and Fueling Collaboration in Oncology: With D. Ross Camidge, MD, PhD; and Mary Redman, PhD
Drs Camidge and Redman discuss Dr Redman’s role as a biostatistician at Fred Hutch, outlining her work in designing clinical trials.
An Overview of the Treatment Landscape for EGFR-mutated NSCLC
A panelist discusses how EGFR-mutated NSCLC treatment has evolved to include multiple generations of EGFR tyrosine kinase inhibitors as first-line therapy, with newer agents showing…
2024 Year in Pictures
The past year has been marked by exceptional achievements and inspiring moments, many captured by our photographers. We’ve collected pictures and stories from throughout 2024.
Clive Peedell (@drpeedell.bsky.social)
Consultant Clinical Oncologist NHS advocate and campaigner Politically centre left Wealth inequality creates health inequality
Isa-RVd Induction Provides Significant PFS Benefit in Newly Diagnosed Multiple Myeloma
Isa-RVd given as induction treatment without consolidation led to a 30% reduction in the risk of disease progression or death vs RVd in multiple myeloma.